GBCC, formerly known as Interpark Bioconvergence Corporation, is one of the earliest organizations developing patient derived organoids (PDOs) in global scale. We have over 500 PDOs from lung, gastric and colorectal cancer patients and are also developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our CRISPR-based PDO platform. Beyond cancer, GBCC is conducting research on brain organoid from human iPSC for disease modeling and regenerative medicine. In addition, we are developing human derived probiotics not only as health functional foods but also therapeutic agents through functional evaluation using our colon PDOs. | Gradiant Bioconvergence (GBCC) is one of the earliest organizations developing patient derived cancer organoids (PDOs) in global scale. We have built Asia’s largest repository of PDOs with next-generation sequencing of over 600 models from lung, gastric and colorectal cancer patients. In addition, we are developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC is establishing brain organoids from human iPSCs for disease modeling and regenerative medicine. | Gradiant Bioconvergence (GBCC) is one of the earliest organizations developing patient derived cancer organoids (PDOs) in global scale. We have built one of Asia’s largest repository of PDOs with next-generation sequencing of over 800 models from lung, gastric and colorectal cancer patients. In addition, we are developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC is establishing brain organoids from human iPSCs for disease modeling and regenerative medicine. | xxx
Cyterra GmbH
Designing new-to-nature terpenes for next-generation ingredients. Cyterra develops programmable terpene chemistry to unlock new ingredient opportunities in flavors, fragrances, repellents, and adjacent specialty markets. By combining deep-chemistry-guided enzyme engineering, biocatalysis, and bioprocess design, Cyterra creates access to both established terpene products and new-to-nature terpene ingredients with novel performance profiles. Built on a strong scientific track record and an industry-oriented development model, the company’s vertically integrated technology stack enables faster development cycles, greater predictability, and scalable routes to differentiated molecular value. Based in Mainz, Cyterra is building new biological value chains for industries where innovation, quality, and supply security are critical. We turn terpene complexity into your competitive advantage.
Coherence Biotech Co. Ltd.
Coherence Bio is a lab automation company developing tools to accelerate AI based drug discovery, through end-to-end automation of cell-based testing.
CNCure Co., Ltd.
CNCure is a pioneering biotech startup dedicated to revolutionizing cancer therapy and diagnostics. We specialize in developing bacteria-based cancer immunotherapeutics and theranostic platforms leveraging microbial theapeutics and nuclear medicine. One of our core technologies is the Salmonella-based Armed Microbe (SAM) platform, which utilizes innovative approaches to target tumors and enhance anticancer immune responses. Our flagship products, CNC-101 and CNC-105, directly target tumors, induce immune responses, and establish long-term antitumor immunological memory to prevent recurrence. In addition, CNCure is advancing diagnostic technologies with radiotracer-based tools for the high-sensitivity detection of fatal diseases such as fungal infections. Our [18F]FDS and [18F]DMPY2 tracers enable high-resolution visualization of gram-negative bacterial and fungal infections and malignant melanoma, respectively. CNCure is dedicated to pioneering innovations in cancer treatment, striving to improve patient outcomes and quality of life on a global scale. By actively participating in numerous national and international R&D projects, we continue to drive groundbreaking research and development. Our extensive patent portfolio is a testament to our technological excellence and commitment to shaping the future of oncology. Founded in 2019 by leading experts in cancer immunotherapy and radiopharmaceuticals, CNCure has developed a robust scientific foundation, a cutting-edge technology platform, and a strong pipeline. In the second half of 2024, we were honored to be one of only 14 companies, out of over 100 applicants, selected for Johnson & Johnson’s JLABS Korea program, which aims to accelerate life-science innovation. As we advance the clinical development and commercialization of our theranostic candidates, we actively seek joint-development partnerships and investments to expand our global presence. Our vision is to revolutionize cancer treatment through groundbreaking bacteria-based immunotherapies and radiopharmaceuticals that address critical unmet medical needs. | CNCure Co., Ltd. is a pioneering biotechnology company based in Hwasun, Republic of Korea, dedicated to revolutionizing cancer therapy and diagnostics. Founded in 2019, CNCure specializes in bacteria‑based cancer immunotherapeutics and integrated theranostic platforms leveraging microbial and nuclear medicine. The company’s lead candidate, CNC‑101, is a next‑generation bacterial immunotherapy built on attenuated Salmonella typhimurium technology, designed to selectively colonize the tumor microenvironment and reprogram it into an immuno‑active state that enhances anti‑tumor immune responses. Preclinical data demonstrate promising efficacy and safety profiles across multiple solid tumor models. Beyond immuno‑oncology, CNCure is advancing radiopharmaceutical and theranostic platforms that combine imaging and therapy for improved tumor targeting, treatment monitoring, and personalized decision‑making. CNCure actively pursues global partnerships and business development to translate its innovative platforms into clinical applications that address unmet medical needs. CNCure continues to present its scientific and clinical progress at major international conferences.
Changzhou Smart-Lifesciences Biotechnology Co.,Ltd.
Smart Lifesciences develops innovative scientific products and provides professional one-stop solutions. Our technology platform originated in chromatography and has been applied across the broad field of protein science-from protein preparation to purification, detection, and application development services. For large-scale manufacturing, our active DMF filings enable a seamless workflow to accelerate the translation of research.
CancerFree Biotech
CancerFree Biotech has a patented system to create patient-derived organoids (PDO) using a bionic tumor culture system, which can be used as an avatar to help physicians and patients develop the optimal cancer treatment strategy. The technology uses blood specimens, making it easy and non-intrusive, and has been successful in deriving 130+ different types of solid tumors from real-world cancer patients. CancerFree Biotech is also collaborating with pharmaceutical companies, using their PDO model to predict clinical trial outcomes during the drug development process, potentially helping to validate compounds during the preclinical and clinical trial phases. | CancerFree Biotech has developed a proprietary cancer cell culture system called E.V.A. (Ex Vivo Avatar). E.V.A. combines 3D cell culture scaffolding with AI image recognition to facilitate tumor cell proliferation. Using just 20mL of patient blood, the platform grows tumor cells to generate heterogeneous organoid models that closely mimic the patient’s internal tumor. These models allow pharmaceutical companies to identify the best candidates for clinical trials by validating the efficacy of their drugs in suppressing tumor cells from real patients. | CancerFree Biotech has developed Prometheus Lab AI, a smart-glasses platform that automates R&D lab documentation. With hands-free, real-time workflow capture, Prometheus converts visual input into structured experiment records, reducing manual errors and significantly cutting down on documentation time.